Clinical Research Directory
Browse clinical research sites, groups, and studies.
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Sponsor: Pfizer
Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Official title: MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
187
Start Date
2021-02-02
Completion Date
2026-12-31
Last Updated
2026-05-19
Healthy Volunteers
No
Conditions
Interventions
Elranatamab (PF-06863135)
BCMA-CD3 bispecific antibody
Locations (40)
Beverly Hills Cancer Center
Beverly Hills, California, United States
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
UCLA Hematology/Oncology Clinic
Los Angeles, California, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
Baptist Hospital of Miami
Miami, Florida, United States
Miami Cancer Institute
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States
Northwestern Medical Group
Chicago, Illinois, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Loyola University Chicago performing research at Loyola University Medical Center
Maywood, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
Norton Women's and Children's Hospital
Louisville, Kentucky, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Regional Cancer Care Associates, LLC
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
Long Island City, New York, United States
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, United States
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, United States
St Francis Physician Services Inc
Greenville, South Carolina, United States
Baylor Scott & White Research Institute
Dallas, Texas, United States
St Vincent's Hospital (Melbourne)
Fitzroy, Victoria, Australia
The Alfred
Melbourne, Victoria, Australia
Epworth Healthcare
Richmond, Victoria, Australia
CIUSSS-EMTL, Installation Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
CHU de Lille - Hopital Claude Huriez
Lille, France
CHU de Nantes - Hôtel Dieu
Nantes, France
Centre Hospitalier Lyon Sud - Service d'Hematologie Clinique
Pierre-Bénite, France
CHU de Poitiers, Pôle Régional de Cancérologie
Poitiers, France
Universitätsklinikum Hamburg - Eppendorf
Hamburg, Germany
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy
Bydgoszcz, Poland
Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu
Poznan, Poland
Clinica Universitaria de Navarra
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Doctor Peset
Valencia, Spain